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A-type natriuretic peptide (ANP) and adrenomedullin (ADM)
are potent hypotensive, diuretic, and natriuretic peptides
involved in maintaining cardiovascular and renal
homeostasis. We conducted a prospective 7-year study of
177 nondiabetic patients with primary chronic kidney
disease to see if ANP and ADM plasma concentrations predict
the progression of their disease, using novel sandwich
immunoassays covering the midregional epitopes of the
stable prohormones (MRproANP and MR-proADM).
Progression of chronic kidney disease was defined as
doubling of baseline serum creatinine and/or terminal renal
failure, which occurred in 65 patients. Analysis of the receiver
operating characteristic curve for the prediction of renal
endpoints showed similar areas under the curve for the
glomerular filtration rate (GFR) (0.838), MR-proANP (0.810),
and MRproADM (0.876), respectively, as did the Kaplan–Meier
curve analyses of the patients stratified according to the
median of the respective markers. In separate multiple Cox-
proportional hazard regression analyses, increased plasma
concentrations of both peptides were each strongly
predictive of the progression of chronic kidney disease after
adjustments for age, gender, GFR, proteinuria and amino-
terminal pro-B-type natriuretic peptide. Our study suggests
that MR-proANP and MR-proADM are useful new markers of
progression of primary nondiabetic chronic kidney disease.
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Chronic kidney disease (CKD) is a major health problem
with increasing incidence and prevalence, high costs, and
poor outcomes.1 Introduction of the kidney disease outcome
quality initiative (K/DOQI) classification and the widespread
use of estimated glomerular filtration rate (GFR) to assess
renal function have identified large numbers of patients with
previously undiagnosed CKD.2,3 However, only a minority of
CKD patients ever advance to end-stage renal disease
(ESRD).4 The identification of those patients with the
greatest risk for CKD progression remains a challenge.
Recently, we demonstrated that N-terminal proBNP (NT-
proBNP), a well-established prognostic marker for cardio-
vascular disease, predicts kidney disease progression in
nondiabetic patients with primary CKD.5 There exist two
other interesting candidate peptides for the prognosis of
CKD patients, namely A-type natriuretic peptide (ANP) and
adrenomedullin (ADM). Both peptides are potent hypoten-
sive, diuretic, and natriuretic peptides involved in maintain-
ing cardiovascular and renal hemostasis.6,7 Increased plasma
concentrations of ANP and ADM have been reported in
patients with cardiovascular disease and in patients with
kidney disease.8–11 However, it remains unclear whether
increased ANP and ADM plasma concentrations predict
progression of kidney disease.
The aim of this study was therefore to investigate the
predictive value of ANP and ADM, using novel sandwich
immunoassays covering the midregional epitopes of the more
stable prohormones (MR-proANP and MR-proADM),12,13
for kidney disease progression in a prospective 7-year follow-
up study in a cohort of nondiabetic patients with primary
CKD, which is called the Mild-to-Moderate Kidney Disease
(MMKD) study.
RESULTS
Table 1 shows NT-proBNP, MR-proANP, and MR-proADM
plasma concentrations at baseline GFR stratified in stages
according to the K/DOQI clinical practice guidelines
for CKD. There was a continuous increase of median
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NT-proBNP, MR-proANP, and MR-proADM plasma
concentrations across the CKD stages. Furthermore, non-
parametric correlation analyses revealed significant associa-
tions between GFR and all three parameters (Table 2).
Follow-up was available in 177 out of the 227 enrolled
patients. The median duration of follow-up after completion of
the baseline investigation was 53 months (range 3–84 months).
During follow-up 65 patients progressed to the end point that
was doubling of serum creatinine without reaching ESRD in 36
patients and ESRD requiring renal replacement therapy in 29
patients. Table 3 reports the baseline CKD patient character-
istics for the progressors and nonprogressors. Patients who
reached the progression end point were older, had higher
protein excretion rates as well as lower GFR. In addition,
median plasma concentrations of NT-proBNP, MR-proANP,
and MR-proADM were higher in the progressors than in
nonprogressors (NT-proBNP, 321 vs 84 ng/l; MR-proANP, 164
vs 74 pmol/l; and MR-proADM, 1.13 vs 0.55 nmol/l).
Figure 1 illustrates the area under the curves (AUCs) to
distinguish between patients with and without progression of
CKD. The AUCs were 0.838 (95% CI 0.774–0.890) for GFR,
0.752 (95% CI 0.681–0.815) for NT-proBNP, 0.810 (95% CI
0.743–0.866) for MR-proANP, and 0.876 (95% CI
0.817–0.922) for MR-proADM. The comparison of the
Receiver-operating characteristic curves revealed significant
differences between the AUCs of GFR and NT-proBNP
(difference of AUCs, 0.086; 95% CI 0.008–0.164; P¼ 0.030),
between the AUCs of NT-proBNP and MR-proANP (differ-
ence of AUCs, 0.058; 95% CI 0.009–0.106; P¼ 0.020), and
between the AUCs for NT-proBNP and MR-proADM
(difference of AUCs, 0.124; 95% CI 0.058–0.189; Po0.001),
in predicting kidney disease progression. In contrast, there
was no significant difference between the AUCs of GFR and
MR-proANP (difference of AUCs, 0.029; 95% CI
0.039–0.096; P¼ 0.41) and between the AUCs of GFR and
MR-proADM (difference of AUCs, 0.038; 95% CI
0.013–0.089; P¼ 0.15), respectively.
Kaplan–Meier curve analyses of the 177 patients with CKD
who were stratified into two groups according to the median
of GFR, NT-proBNP, MR-proANP, and MR-proADM at
baseline are shown in Figure 2. Patients who had GFR values
below the median and NT-proBNP, MR-proANP, and MR-
proADM plasma concentrations above the median had a
worse renal prognosis and significant shorter progression
time compared with patients with GFR values above the
median and NT-proBNP, MR-proANP, and MR-proADM
plasma concentrations below the median (mean time to
progression in months was 49.0 (95% CI 43.1–55.0) vs 75.2
Table 1 | Baseline clinical and laboratory data of 227 patients stratified according to GFR in National Kidney Foundation stages
GFR (ml/min per 1.73 m2)
X90 (n=72) 60–89 (n=49) 30–59 (n=63) o30 (n=43) P-value
Gender (male/female), n (%) 50/22 (69.4/30.6) 34/15 (69.4/30.6) 44/19 (68.8/30.2) 26/17 (60.5/39.5) 0.72
Age (years) 39.9±13.2 46.1±11.6 45.9±11.5 54.4±8.5 o0.001
Body mass index (kg/m2) 24.0±3.3 25.6±3.8 25.4±3.4 26.1±4.8 0.02
Current smokers, n (%) 18 (25) 11 (22) 11 (18) 9 (21) 0.97
Systolic blood pressure (mm Hg) 134±21 140±24 139±19 137±19 0.21
Diastolic blood pressure (mm Hg) 84±13 88±15 88±14 88±13 0.20
Serum creatinine (mg/100 ml) 1.14±0.22 1.54±0.45 2.31±0.79 3.63±1.28 o0.001
(0.95;1.11;1.30) (1.25;1.43;1.70) (1.70;2.18;2.80) (2.73;3.50;4.61)
GFR (ml/min per 1.73 m2) 120±28 74±9 44±7 19±7 o0.001
(97;110;132) (65;71;81) (38;44;50) (12;18;26)
Proteinuria (g/24 h per 1.73 m2) 0.60±0.66 1.10±1.10 1.08±0.94 1.03±0.81 0.004
(0.13;0.36;0.82) (0.16;0.57;1.93) (0.27;0.81;1.83) (0.36;0.89;1.52)
Serum albumin (g/100 ml) 4.70±0.38 4.46±0.50 4.55±0.38 4.53±0.34 0.01
High sensitivity C-reactive protein (mg/l) 0.21±0.27 0.32±0.33 0.23±0.21 0.35±0.38 0.01
(0.04;0.09;0.23) (0.13;0.21;0.42) (0.06;0.14;0.36) (0.08;0.18;0.53)
NT-proBNP (ng/l)a 64±76 180±221 380±616 769±846 o0.001
(22;39;76) (45;91;199) (78;173;409) (232;456;1002)
MR-proANP (pmol/l)a 56±28 95±49 159±123 279±161 o0.001
(37;49;68) (60;78;120) (82;130;193) (168;248;339)
MR-proADM (nmol/l)a 0.43±0.12 0.65±0.20 0.90±0.30 1.34±0.39 o0.001
(0.33;0.42;0.49) (0.50;0.63;0.78) (0.69;0.89;1.01) (1.15;1.28;1.52)
GFR, glomerular filtration rate; MR-proADM, midregional pro-adrenomedullin; MR-proANP, midregional pro-A-type natriuretic peptide; NT-proBNP, N-terminal pro-B-type
natriuretic peptide.
P-values are for comparison across all four groups obtained from Kruskal–Wallis test, one-way ANOVA, and w2-test, where appropriate.
Data are presented as mean±s.d. and 25th, 50th (=median), and 75th percentiles for skewed variables where appropriate.
aPlasma levels of NT-proBNP, MR-proANP, and MR-proADM were available in 222, 221, and 220 of the 227 patients, respectively.
Table 2 | Spearman correlation coefficient (P-value) between
the variables GFR, NT-proBNP, MR-proANP, and MR-proADM
plasma concentrations in the 227 patients enrolled at
baseline
NT-proBNP MR-proANP MR-proADM
GFR 0.609 (o0.001) 0.705 (o0.001) 0.815 (o0.001)
NT-proBNP 0.888 (o0.001) 0.737 (o0.001)
MR-proANP 0.845 (o0.001)
GFR, glomerular filtration rate; MR-proADM, midregional pro-adrenomedullin; MR-
proANP, midregional pro-A-type natriuretic peptide; NT-proBNP, N-terminal pro-B-
type natriuretic peptide.
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(95% CI 70.3–80.1), Po0.001 for GFR; 52.5 (95% CI
46.4–58.6) vs 72.3 (95% CI 66.4–78.2), Po0.001 for NT-
proBNP; 51.1 (95% CI 45.2–57.1) vs 71.4 (95% CI 64.7–78.1),
Po0.001 for MR-proANP; and 51.6 (95% CI 45.6–57.6) vs
73.6 (95% CI 68.5–78.6), Po0.001 for MR-proADM,
respectively). Univariate Cox proportional-hazards regression
analyses using the approach of stratifying the predictor
variables according to the median values revealed signifi-
cantly decreased hazard ratios (HRs) for GFR above the
median (HR 0.12; 95% CI 0.06–0.24; Po0.001) and
significantly increased HRs for concentrations above the
median at baseline for NT-proBNP (HR 3.84; 95% CI
2.14–6.89; Po0.001), MR-proANP (HR 4.47; 95% CI
2.46–8.12; Po0.001), and MR-proADM (HR 5.84; 95% CI
3.04–11.21; Po0.001).
The results of Cox proportional-hazards regression
analyses using an incremental approach for the predictor
variables are given in Table 4. In the age- and sex-adjusted
model 1 GFR, proteinuria, NT-proBNP, MR-proANP, and
MR-proADM revealed significant HR for kidney disease
progression. After further adjustment for GRF and protei-
nuria, the HR for MR-proANP and MR-proADM where
slightly attenuated but both variables remained strongly
associated with disease progression, whereas the HR for NT-
proBNP was no longer significant (model 2). Even after
additional adjustment for NT-proBNP both, MR-proANP
and MR-proADM, each remained a strong predictor of
kidney disease progression (model 3). As several of
the investigated variables were non-normally distributed,
we performed a sensitivity analysis by including the
ln-transformed variables into the model. These analyses
revealed very similar results (data not shown) with the
exception of NT-proBNP that remained significant after
adjustment for age, sex, GFR, and proteinuria (HR 1.59; 95%
CI 1.15–2.19; P¼ 0.005). For a better interpretability of the
estimates, however, we present data on the original scale.
We furthermore investigated whether both MR-proANP and
MR-proADM independently add to the prediction of CKD
progression by including both variables in the same Cox
regression model and adjusting for age, sex, GFR, and proteinuria.
The HRs of both variables decreased (compared with the
estimates in model 2 of Table 4) but still remained significant
(HR 1.60; 95% CI 1.11–2.30; P¼ 0.011, for MR-proANP and HR
1.96; 95% CI 1.31–2.94; Po0.001 for MR-proADM).
In a secondary analysis, we included only patients in stage
3 and higher according to K/DOQI clinical practice guide-
lines for CKD (GFR o60 ml/min per 1.73 m2). We observed
very similar estimates as presented for models 2 and 3 of
Table 4 for the entire group (data not shown).
Table 3 | Baseline clinical and laboratory data of 177 patients with completed follow-up with further stratification of those with
and without progression of kidney disease during the follow-up period
Non-progressors (n=112) Progressors (n=65) P-value
Gender (male/female), n (%) 74/38 (66/34) 44/21 (68/32) 0.83
Age (years) 44.8±12.6 49.1±11.1 0.03
Body mass index (kg/m2) 24.9±3.5 25.7±3.9 0.13
Current smokers, n (%) 18 (16) 16 (25) 0.21
Systolic blood pressure (mm Hg) 136±22 137±17 0.72
Diastolic blood pressure (mm Hg) 86±14 88±12 0.34
Serum creatinine (mg/100 ml) 1.54±0.61 (1.14;1.40;1.80) 3.21±1.31 (2.21;3.10;3.94) o0.001
Glomerular filtration rate (ml/min per 1.73 m2) 79±38 (50;74;99) 38±25 (20;33;46) o0.001
Proteinuria (g/24 h per 1.73 m2) 0.87±0.95 (0.14;0.46;1.25) 1.25±0.83 (0.61;1.09;1.78) o0.001
Serum albumin (g/100 ml) 4.57±0.43 4.53±0.36 0.50
High sensitivity C-reactive protein (mg/l) 0.28±0.32 (0.07;0.17;0.39) 0.29±0.31 (0.08;0.16;0.43) 0.59
NT-proBNP (ng/l)a 182±305 (44;84;176) 579±717 (117;321;745) o0.001
proANP (pmol/l)a 97±66 (48;74;128) 225±171 (111;164;274) o0.001
proADM (nmol/l)a 0.63±0.28 (0.43;0.55;0.79) 1.15±0.42 (0.91;1.13;1.36) o0.001
GFR, glomerular filtration rate; MR-proADM, midregional pro-adrenomedullin; MR-proANP, midregional pro-A-type natriuretic peptide; NT-proBNP, N-terminal pro-B-type
natriuretic peptide.
Data are presented as mean±s.d. and 25th, 50th (=median), and 75th percentiles for skewed variables where appropriate.
aPlasma levels of NT-proBNP, MR-proANP, and MR-proADM were available in 174, 174, and 173 of the 177 patients, respectively.
Se
ns
itiv
ity
 (%
)
100
80
60
40
20
0
100-specificity (%)
0 20 40 60 80 100
Figure 1 | Prediction of chronic kidney disease progression.
Receiver-operating characteristic (ROC) plot demonstrating the
ability of GFR, NT-proBNP, MR-proANP, and MR-proADM to
predict kidney disease progression in patients with CKD; the areas
under curve were 0.838 for GFR (black line), 0.752 for NT-prBNP
(red line), 0.810 for MR-proANP (green line), and 0.876 for MR-
proADM (blue line).
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DISCUSSION
The present study is the first prospective long-term
observation investigating the prognostic value of MR-
proANP and MR-proADM for renal disease progression in
Caucasian patients with primary nondiabetic CKD. Our data
indicate that increased MR-proANP and MR-proADM
plasma concentrations at baseline are strong predictors of
renal end points that are even independent from GFR.
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Figure 2 | Prediction of chronic kidney disease progression. Kaplan–Meier plots showing renal disease progression in patients with CKD
who were stratified into two groups according to the medians of baseline GFR (54 ml/min per 1.73 m2, a), NT-proBNP (119 ng/l, b), MR-
proANP (106 pmol/l, c), and MR-proADM (0.75 nmol/l, d) at baseline.
Table 4 | The association of baseline variables with progression of kidney disease during the observation period using multiple
Cox-proportional hazards regression models
Model 1 Model 2 Model 3
Adjusted for age and sex
Adjusted for age, sex, GFR, and
proteinuria
Adjusted for age, sex, GFR, proteinuria,
and NT-proBNP
Variable (increment) HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
GFR (per 1 s.d. increase)a 0.21 (0.13–0.34) o0.001 – –
Proteinuria (per 1 s.d. increase)b 1.27 (1.02–1.58) 0.032 – –
NT-proBNP (per 1 s.d. increase)c 1.45 (1.24–1.69) o0.001 1.15 (0.96–1.38)d 0.127 –
MR-proANP (per 1 s.d. increase)e 2.88 (2.25–3.68) o0.001 2.11 (1.59–2.80)d o0.001 2.90 (1.94–4.34)f o0.001
MR-proADM (per 1 s.d. increase)g 3.41 (2.61–4.45) o0.001 2.60 (1.85–3.64)d o0.001 2.62 (1.84–3.74)f o0.001
GFR, glomerular filtration rate; MR-proANP, midregional pro-A-type natriuretic peptide; MR-proADM, midregional pro-adrenomedullin, NT-proBNP, N-terminal pro-B-type
natriuretic peptide.
aFor GFR 1 s.d. increment was 39 ml/min per 1.73 m2.
bFor proteinuria it was 0.92 g/24 h per 1.73 m2.
cFor NT-proBNP it was 527 ng/l.
dMR-proANP, MR-proADM, and NT-proBNP were not included at the same time, but were adjusted for the same variables: age, sex, GFR, proteinuria.
eMR-proANP it was 131 pmol/l.
fMR-proANP and MR-proADM were not included at the same time, but were adjusted for the same variables: age, sex, GFR, proteinuria, and NT-proBNP.
gFor MR-proADM it was 0.42 nmol/l, respectively.
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Through the adoption of the K/DOQI recommendations
and routinely reported estimates of GFR by many labora-
tories, substantial success has been achieved in screening for
undiagnosed CKD.2,3 However, there is an urgent need for
further risk stratification and the identification of further risk
predictors to target interventions to those patients with CKD
most likely to progress to ESRD.
An important finding of our study was the fact that MR-
proANP and MR-proADM were strongly correlated with
GFR measured by iohexol, which has been reported to come
close to the gold standard of measuring kidney function.14
We observed a continuous increase in MR-proANP and MR-
proADM plasma concentrations across GFR stages, indicat-
ing an association with disease severity. This strong
correlation with GFR may be attributable to the evidence
that ANP and ADM are produced in the kidney,15 and both
have important biological functions within the kidney.6,16
Furthermore, renoprotective properties for both peptides
have been reported, suggesting a compensatory role of
increased concentrations of ANP and ADM in CKD.6,15,16
In the setting evaluated, the prognostic values of MR-
proANP and MR-proADM were comparable with that of
GFR, an established prognostic marker in kidney disease
progression.2 This was demonstrated by similar AUCs for
both analytes when compared with GFR. In addition,
Kaplan–Meier curve analyses for patients stratified according
the median of markers displayed similar results for GRF, MR-
proANP, and MR-proADM. Furthermore, in the age- and
sex-adjusted Cox proportional-hazard regression models, the
behavior of GFR, MR-proANP, and MR-proADM was similar
as well. However, it is important to note that besides GFR
both MR-proANP and MR-proADM added significantly to
the prediction of disease progression. An increase of each of
both parameters by one standard deviation was associated
with more than twice the risk of disease progression even
after adjustment for baseline GFR. Even if we added both
parameters at the same time to the model resulted in a
significant and independent contribution of both parameters
to the risk prediction. This additional analysis, however, has
to be considered with caution due to the multicollinearity of
the two highly correlated parameters (r¼ 0.845; Table 2).
We have previously demonstrated in the same cohort that
NT-proBNP levels predict renal end points, after log
transformation also independently of possible confounders.
In our extension of this study, the prognostic ability of NT-
proBNP was lower compared with GFR, MR-proANP, or
MR-proADM. Although the reason for this finding is unclear,
one could speculate that increased concentrations of NT-
proBNP might mainly reflect cardiac dysfunction, whereas
MR-proANP and MR-proADM might give more pronounced
information about impaired kidney function beyond their
association with changes in hemodynamics.
Replacing the problematic measurement of bioactive
rapidly cleared peptides by measuring the nonfunctional,
stable peptides derived from their precursors has been
applied successfully for A- and B-type natriuretic peptides
(that is, ANP vs NT-proANP and BNP vs NT-proBNP). This
is of even greater importance if long-term stored samples are
analyzed because the active hormones unlike the propeptides
undergo degradation even in frozen samples. NT-proANP
occurs mainly in a high-molecular mass form with longer
half-life than the active hormone, but it may also be cleaved
into smaller fragments in vivo,17,18 which might translate into
underestimation of the analyte concentration in immunoas-
says, depending on the assay design.18 Proteolytic degrada-
tion of proANP seems to be mainly directed to the N- and C-
terminal parts, whereas the midregion is significantly more
stable.18 In this study we therefore used a novel sandwich
assays for the measurement of the more stable prohormone
of midregional proANP (MR-proANP).12 As direct measure-
ment of ADM in the circulation is also difficult due to its
short half-life,19 and its immediate binding to receptors,20 its
interaction with binding proteins,21 as well as several
technical difficulties,21 the clinical use of ADM measurement
has been limited. Therefore, indirect assessment of ADM
release by measurement of the MR-proADM fragment might
represent a valuable progress for clinical practice.
Strengths and limitations of the study
It is important to note that GFR in our study was not
calculated by a formula but was measured by iohexol
clearance which is considered an exact method to measure
kidney function.14 This method, however, is laborious and is
a burden for the patient due to the application of contrast
media and the collection of several blood samples. Measure-
ment of MR-proANP or MR-proADM is an alternative and
simple method which provides a good approximation of
kidney function and a well-performing predictor for the
progression of kidney disease which performs equal to GFR.
Our study does have some potential limitations. We
acknowledge missing follow-up data on 50 (22%) patients of
the baseline cohort. However, as these patients had a far
better kidney function at baseline than the patients under
prospective observation, we assume that most of them
remained stable without symptoms over years and therefore
were not referred by the physicians for follow-up investiga-
tions. Because there are no echocardiographic data on the
participants of the Mild-to-Moderate Kidney Disease Study
at baseline or during the follow-up period, we are unable to
elucidate whether MR-proANP and MR-proADM are
associated with CKD progression independently of the
presence of structural and/or functional cardiac disease.
Furthermore, as we studied patients with nondiabetic CKD
considering several exclusion criteria as described in the
methods, it has to be investigated whether increased MR-
proANP and MR-proADM will predict kidney disease
progression in other types of CKD such as diabetic
nephropathy, other ethnicities, or CKD patients 465 years
of age.
In summary, our work shows that increased MR-proANP
and MR-proADM plasma concentrations at baseline
are powerful predictors of progression of kidney disease.
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Therefore, both markers might be clinically useful as
predictors in patients with primary nondiabetic CKD.
METHODS
Study sample
At baseline, 227 Caucasian patients aged between 18 and 65 years
with nondiabetic CKD and various degrees of renal impairment
were enrolled into the Mild-to-Moderate Kidney Disease Study.
These patients were recruited from eight nephrology departments in
Germany, Austria, and South Tyrol as described earlier.22 This study
was approved by the Institutional Ethic Committees, and all subjects
gave written informed consent. They had stable renal function for at
least 3 months before entry into the study. Exclusion criteria were
treatment with immunosuppressive agents, fish oil or erythropoie-
tin, serum creatinine above 6 mg/100 ml, diabetes mellitus of any
type, malignancy, liver, thyroid, or infectious disease, nephrotic
syndrome (defined as proteinuria 43.5 g/1.73 m2 per day), organ
transplantation, allergy to ionic contrast media and pregnancy. In
order to avoid interobserver differences, all patients were recruited
by one physician who visited all participating centers. Patient
history, including smoking habits and antihypertensive treatment at
baseline was recorded by interview and confirmed by checking
patient records. This was complemented by clinical examination
including assessment of body mass index and blood pressure.
Hypertension was defined as blood pressure above 140/90 mm Hg
and/or the use of antihypertensive medication. Antihypertensive
medication was withheld on the day of study enrollment in order to
minimize interference with measurements of GFR. Antihypertensive
drugs were taken by 179 patients (79%): diuretics (n¼ 83; 37%),
ACE inhibitors (n¼ 123; 54%), calcium channel blockers (n¼ 78;
34%), b-receptor blockers (n¼ 67; 30%), and a-1-receptor blockers
(n¼ 36; 16%).
The primary cause of kidney disease was glomerulonephritis in
97 (biopsy-confirmed in 90) patients, adult polycystic kidney disease
in 37 patients, interstitial nephritis in 24 patients, other types of
kidney disease in 43 patients, and unknown in 26 patients. The
distribution of patients over the stages of CKD according to the K/
DOQI clinical practice guidelines for CKD classification2 is provided
in Table 1.
The end point of the follow-up investigation was defined as
doubling of baseline serum creatinine and/or ESRD necessitating
renal replacement therapy. Of the primary cohort of 227 patients,
177 patients (78%) were followed prospectively over a period of up
to 84 months.23 Patients were under regular control in the
outpatient ward and end points were reported to the study
coordinating center. Patients, who were lost during follow-up, had
moved home or were not referred to the study centers after baseline
investigation. Compared with patients with follow-up, these patients
had significantly better renal function at baseline but did not differ
significantly in gender and age.23
Biochemical analysis
Blood samples were drawn after an overnight fast of at least 12 h.
The samples were immediately centrifuged at 1500 g and 4 1C for
10 min, and the supernatants stored in aliquots at 80 1C until
further use. GFR was assessed in patients using the iohexol clearance
technique as described in detail elsewhere.14 Routine biochemical
analyses, including serum ceatinine, proteiunria, serum albumin,
and high-sensitivity C-reactive protein, were performed as described
previously.22 Plasma NT-proBNP was measured on a Modular
Analytics E170 System (Roche Diagnostics, Mannheim, Germany).5
MR-proANP and MR-proADM plasma concentrations were mea-
sured by commercially available immunoluminometric assays
(B.R.A.H.M.S AG, Henningsdorf, Germany). The precision of these
two methods has been evaluated and described previously.12,13
Statistical analysis
Statistical analysis was performed using the SPSS version 13.0
software (SPSS Inc., Chicago, IL, USA), and the MedCalc 9.4.2.0
package (MedCalc Software, Mariakerke, Belgium). Univariate
comparisons of continuous variables between various groups were
performed using one-way analysis of variance, unpaired t-test or the
nonparametric Kruskal–Wallis or Wilcoxon rank sum test in case of
non-normally distributed variables. Dichotomized variables were
compared using Pearson’s w2-test. Data are presented as mean±s.d.
and as median and 25th and 75th percentiles for skewed variables
where appropriate. The Spearman coefficient of rank correlation (rs)
was used to assess the relationship between the four main study
parameters (that is, GFR, NT-proBNP, MR-proANP, and MR-
proADM). Receiver-operating characteristic plots were analyzed and
the areas under the curve were calculated for all four analytes. AUCs
were compared according to the method of Hanley and McNeil.24
Kaplan–Meier estimates of the distribution of times from baseline to
renal end points were generated, for patients with GFR, NT-proBNP,
MR-proANP, and MR-proADM above and below the median value
of the entire study population; log-rank tests were calculated to
compare the survival curves between the groups. Univariate Cox
proportional-hazards regression analysis was performed, with all
four parameters dichotomized according to the median concentra-
tion of the entire cohort. In addition, adjusted risk estimates for
progression end points were calculated using an incremental
approach for each increment of 1 s.d. of the respective data. All
probabilities were two-tailed and P values o0.05 were regarded as
significant.
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